Antiviral therapy of chronic hepatitis C: 30 years success story

Abstract


Exactly 30 years ago, hepatitis C virus was identified. Over the years, tremendous success has been achieved in the treatment of hepatitis C, which is currently considered to be an almost completely curable disease. The review presents the main stages in the development of hepatitis C antiviral therapy, the efficacy of various treatment regimens. The greatest progress in treatment was noted over the past 5 years when drugs with direct antiviral action appeared and began to be widely used, including in Russia, which ensure the elimination of the virus in 90-95% of cases.

Full Text

Restricted Access

About the authors

D T Abdurakhmanov

Tareev Clinic of Rheumatology Nephrology and Occupational Disease Sechenov First Moscow State Medical University

Email: abdjamal@mail.ru
Moscow, Russia

T P Rozina

Tareev Clinic of Rheumatology Nephrology and Occupational Disease Sechenov First Moscow State Medical University

Moscow, Russia

E N Nikulkina

Tareev Clinic of Rheumatology Nephrology and Occupational Disease Sechenov First Moscow State Medical University

Moscow, Russia

E Z Burnevich

Tareev Clinic of Rheumatology Nephrology and Occupational Disease Sechenov First Moscow State Medical University

Moscow, Russia

E L Tanashuk

Tareev Clinic of Rheumatology Nephrology and Occupational Disease Sechenov First Moscow State Medical University

Moscow, Russia

M V Severov

Tareev Clinic of Rheumatology Nephrology and Occupational Disease Sechenov First Moscow State Medical University

Moscow, Russia

A L Filatova

Tareev Clinic of Rheumatology Nephrology and Occupational Disease Sechenov First Moscow State Medical University

Moscow, Russia

S Yu Milovanova

Tareev Clinic of Rheumatology Nephrology and Occupational Disease Sechenov First Moscow State Medical University

Moscow, Russia

V V Karpov

Tareev Clinic of Rheumatology Nephrology and Occupational Disease Sechenov First Moscow State Medical University

Moscow, Russia

S V Moiseev

Tareev Clinic of Rheumatology Nephrology and Occupational Disease Sechenov First Moscow State Medical University

Moscow, Russia

References

  1. Feinstone S.M, Kapikian A.Z, Purcell R.H, Alter H.J, Holland P.V. Transfusion - associated hepatitis not due to viral hepatitis type A or B. N Engl J Med. 1975;292,767-70. doi: 10.10 56/NEJM197504102921502
  2. Berman M, Alter H.J, Ishak K.G, Purcell R.H, Jones E.A. The chronic sequelae of non-A, non-B hepatitis. Ann Intern Med. 1979;91:1-6. doi: 10.7326/0003-4819-91-1-1
  3. Сергиев П.Г., Тареев Е.М., Гонтаева А.А. и др. Вирусная желтуха (эпидемический гепатит в связи с иммунизацией человеческой сывороткой). Терапевтический архив. 1940;17(6):596-611.
  4. Choo Q.L, Kuo G, Weiner A.J, et al. Isolation of a cDNA clone derived from a blood - borne non-A, non-B viral hepatitis genome. Science. 1989;244:359-62. doi: 10.1126/science.2523562
  5. Marcellin P. Hepatitis B and hepatitis C in 2009. Liver International. 2009;29(s1):1-8. doi: 10.1111/j.1478-3231.2008.01947.x
  6. Cooke G, Andrieux-Meyer I, Applegate T, et al. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2019;4:135-84. doi: 10.1016/S2468-1253(18)30270-X
  7. Davis G.L, Balart L.A, Schiff E.R, Lindsay K, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Eng J Med. 1989;321(22):1501-06. doi: 10.1056/NEJM198911303212203
  8. Brillanti S, Garson J, Foli M, Whitby K, et al. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa - resistant chronic hepatitis C. Gastroenterology. 1994; 107(3):812-7. doi: 10.1016/0016-5085(94)90131-7
  9. Manns M.P, McHutchison J.G, Gordon S.C, Rustgi V.K, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(22):958-65. doi: 10.1016/s0140-6736(01)06102-5
  10. Fried M.W, Shiffman M.L, Reddy K.R, Smith C, Marinos G, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975-82. doi: 10.1056/NEJMoa020047
  11. Nahon P, Bourcier V, Layese R, Audureau E, Cagnot C, et al. Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications. Gastroenterology. 2017;152(1):142-56. doi: 10.1053/j.gastro
  12. Simmons B, Saleem J, Heath K, et al. Long - term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta - analysis of the survival benefit of achieving a sustained virological response. Clin Infect Dis. 2015;61:730-40. doi: 10.1093/cid/civ396
  13. Poordad F, Mc Cone J, Bacon B.R, Bruno S, et al. Boceprevir for Untreated Chronic HCV Genotype 1 Infection. N Engl J Med. 2011;364:1195-206. doi: 10.1056/NEJMoa1010494
  14. Jacobson I.M, Mc Hutchison J.G, Dusheiko G, Di Bisceglie A.M, et al. N Engl J Med. 2011;364:2405-16. doi: 10.1056/NEJMoa1012912
  15. Colombo M, Fernández I, Abdurakhmanov D, Ferreira Р.А, et al. Safety and on - treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C. Gut. 2014;63:1150-8. doi: 10.1136/gutjnl-2013-305667
  16. Jacobson I, Zeuzem S, Flisiak R, Knysz B, et al. Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1. World J Gastroenterol. 2016;22(12):3418-31. doi: 10.3748/wjg.v22.i12.3418
  17. Lawitz E, Sulkowski M.S, Ghalib R, Rodriguez-Torres M, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non - responders to pegylated interferon and ribavirin and treatment - naive patients: the COSMOS randomised study. Lancet. 2014;384(9956):1756-65. doi: 10.1016/S0140-6736(14)61036-9
  18. Manns M, Pol S, Jacobson I.M, Marcellin P, et al. All - oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet. 2014; 384(9954):1597-605. doi: 10.1016/S0140-6736(14)61059-X
  19. Feld J.J, Kowdley K.V, Coakley E, Sigal S, et al. Treatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin. N Engl J Med. 2014;370:1594-603. doi: 10.1056/NEJMoa13157 22
  20. Sulkowski M.S, Gardiner D.F, Rodriguez-Torres M, Reddy K.R, et al. Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection. N Engl J Med. 2014;370:211-21. doi: 10.1056/NEJMoa1306218
  21. Isakov V, Chulanov V, Abdurakhmanov D, Burnevich E, et al. Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase-3, open - label study in Russia and Sweden. Infect Dis (Lond). 2019;51(2):131-9. doi: 10.1080/23744235.2018.1535186
  22. Jacobson I.M, Lawitz E, Gane E.J, Willems B.E, et al. Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials. Gastroenterology. 2017;153(1):113-22. doi: 10.1053/j.gastro.2017.03.047
  23. Zeuzem S, Foster G.R, Wang S, Asatryan A, et al. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. N Engl J Med. 2018;378(4):354-69. doi: 10.1056/NEJ Moa1702417
  24. Bourlière M, Gordon S.C, Flamm S.L, Cooper C.L, et al. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. N Engl J Med. 2017;376:2134-46. doi: 10.1056/NEJMoa1613512
  25. Poordad F, Felizarta F, Asatryan A, Sulkowski M.S, et al. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct - acting antiviral treatment. Hepatology. 2017;66(2):389-97. doi: 10.1002/hep.29081
  26. Abdurakhmanov D.T, Rozina T.P, Nikulkina E.N, Nabatchikova E.A, Chulanov V.P, Moiseev S.V. Sofosbuvir - based salvage therapy for HCV infection in cirrhotic patients with DAA failure and multidrug resistance. Antivir Ther. 2018;23(8):705-8. doi: 10.3851/IMP3266
  27. Artemova M, Abdurakhmanov D, Ignatova T, Mukhin N. Persistent Hepatitis C Virus-Associated Cryoglobulinemic Vasculitis Following Virus Eradication After Direct-Acting Antiviral Therapy. Hepatology. 2017;65(5):1770-71. doi: 10.1002/hep.28981
  28. Zubkin M.L, Abdurakhmanov D.T, Sagalova O.I, Bakulin I.G, Maevskaya M.V, Ivashkin V.T. Persistent mixed cryoglobulinemia after successful antiviral treatment of chronic hepatitis C virus infection: What's the next? Scandinavian J Gastroenterology. 2018;53(7):883-4. doi: 10. 1080/00365521.2018.1477988
  29. Gragnani L, Visentini M, Fognani E, Urraro T, et al. Prospective study of guideline - tailored therapy with direct - acting antivirals for hepatitis C virus - associated mixed cryoglobulinemia. Hepatology. 2016;64:1473-82. doi: 10.1002/hep.28753
  30. Calvaruso V, Cabibbo G, Cacciola I, Petta S, et al. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. Gastroenterology. 2018;155(2):411-21. doi: 10.1053/j.gastro.2018.04.008
  31. Lleo A, Aglitti A, Aghemo A, Maisonneuve P, et al. Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. Dig Liver Dis. 2019;51(2):310-17. doi: 10.1016/j.dld.2018.10.014
  32. Ioannou G.N, Green P.K, Berry K. HCV eradication induced by direct - acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol. 2018;68:25-32. doi.org: 10.1016/j.jhep.2017.08.030
  33. Höner Zu Siederdissen C, Maasoumy B, Marra F, Deterding K, et al. Drug-Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort. Clin Infect Dis. 2016;62(5):561-7. doi: 10.1093/cid/civ973
  34. Hudson B, Walker A.J, Irving W.L. Comorbidities and medications of patients with chronic hepatitis C under specialist care in the UK. J Med Virol. 2017;89(12):2158-64. doi: 10.1002/jmv.24848

Statistics

Views

Abstract - 33

PDF (Russian) - 18

Cited-By


PlumX

Dimensions

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:

 

© 2018 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies